

Aug 2025 A monthly electronic bulletin published by the drug sector

Drug Safety Updates

SFDA Approved Risk Management Measures (RMMs)

The summary view in the table includes reviewed and approved Risk minimization measures by SFDA:

Product	Measure
Ariakayce® (Amikacin sulfate)	Patient Alert Card
VENTOLIN EVOHALER® (Salbutamol)	DHPC
VYVANSE® (Lisdexamfetamine Dimesilate)	Safety Communication
CONCERTA® (Methylphenidate)	Safety Communication
CONCENTIA® (Methylphenidate)	Safety Communication
QUILLIVANT XR® (Methylphenidate)	Safety Communication
RITALIN® (Methylphenidate)	Safety Communication

**Measures: additional minimization activities that should be done by the marketing authorization holder to minimize the risk.*